With more than 35 years of experience, we are a leading expert in the conjugation of highly active molecules to monoclonal antibodies for the development and manufacture of antibody-drug conjugates (ADCs).
Antibody-drug conjugation technology uses monoclonal antibodies or other biologics to deliver highly active or potent pharmaceutical ingredients (HPAPIs) to targeted cells. In conjugated form, the HPAPIs exhibits more selective therapeutic activity, sparing non-target cells from many of the toxic effects and improving the safety profile. Customers are quickly adapting these complex technologies and employing them to develop new oncology and non-oncology products that are more targeted and safer.
ChetoSensar™: consider it disSolved. A technology that solves many challenges with antibody-drug conjugates
Do you need to rescue your ADC program? Poor solubility of ADCs represents a significant challenge leading to painstaking efforts to rescue these programs. Our ChetoSensar™ technology can help to improve the solubility of ADCs and provides access to highly hydrophobic novel payloads that might not be considered. Find out how you can try this technology to improve solubility, reduce aggregation, improve therapeutic index & conjugation efficiency, and achieve higher drug-to-antibody ratio for your ADC program.
Our ADC Express™ discovery conjugation services help accelerate production of development-grade ADC constructs with essential analytical characterization of key quality attributes.
The combination of our extensive bioconjugation expertise and proven platform technology will efficiently turn your antibody and/or linker and payload into an ADC, enable scaling and shorten your path to the clinic.
|ADC Express™ Features|
We have the right experience and expertise to support your ADC or bioconjugate project:
Our clinical ADC manufacturing facility was purpose-built for handling HPAPIs, antibodies, linkers and for performing complex conjugation processes in a cGMP suite featuring isolators and specialized handling equipment.
Our 10,000 square foot commercial-scale manufacturing facility supports clinical Phase I/II/III and commercial ADCs and features:
Our BioReliance® Biodevelopment Center at Martillac, France offers state-of-the-art GMP mAb production. Click here to learn more.
Our comprehensive ADC solutions include analytical and process support throughout all stages of drug development and manufacture.
The analytical services include development of specifications, risk assessment, implementation of process controls and validated cleaning procedures. We also offer
From evaluation to execution, our highly skilled and dedicated project managers are responsible for coordinating multi-disciplinary teams, international site activities and timelines:
Our ADC Contract Manufacturing footprint offers integrated solutions for your antibody-drug conjugate. Click here for more information on our comprehensive ADC solutions.
The global footprint of our contract manufacturing services assures you of wide-ranging regulatory and supply expertise, easily accessed through a single trusted partner. Learn more about our locations:
Case Study: Complete Single-Use ADC Technology from Development Through Scale-up
Flyer: ChetoSensar: Consider it DisSolved
Flyer: Discover Comprehensive ADC Solutions
Flyer: ADC Express™ Pre-clinical Conjugation Services for the Best Candidate Selection
Flyer: DM1 - Mertansine GMP Quality Payload for Your Drug Conjugate Programs
Flyer: Synthesise Dolastatin Payloads Faster and with Less Risk
Webinar: The Evolution of ADC Manufacturing Expertise During the Last 10 Years
Webinar: Complete Single-use ADC Technology from Development Through Scale-up
Webinar: Commercializing Antibody-Drug Conjugates: a CMO’s Journey
White Paper: Commercializing Antibody-Drug Conjugates: a CMO’s Journey